The novel oncogenic factor TET3 combines with AHR to promote thyroid cancer lymphangiogenesis via the HIF-1α/VEGF signaling pathway

Liyun Yang; Runyu Zhao; Peipei Qiao; Jiaxin Cui; Xiaoping Chen; Jinping Fan; An Hu; Shuixian Huang

doi:10.1186/s12935-023-03021-6

The novel oncogenic factor TET3 combines with AHR to promote thyroid cancer lymphangiogenesis via the HIF-1α/VEGF signaling pathway

Cancer Cell Int. 2023 Sep 17;23(1):206. doi: 10.1186/s12935-023-03021-6.

Authors

Liyun Yang¹, Runyu Zhao², Peipei Qiao², Jiaxin Cui¹, Xiaoping Chen¹, Jinping Fan³, An Hu⁴, Shuixian Huang⁵

Affiliations

¹ Department of Otolaryngology Head and Neck Surgery, Gongli Hospital, the Second Military Medical University, Shanghai, 200135, China.
² Postgraduate Training Base at Shanghai Gongli Hospital, Ningxia Medical University, Shanghai, 200135, China.
³ Department of Otolaryngology Head and Neck Surgery, Changzheng Hospital, the Second Military Medical University, Shanghai, 200135, China.
⁴ Department of Otolaryngology Head and Neck Surgery, Gongli Hospital, the Second Military Medical University, Shanghai, 200135, China. juanitohuan@163.com.
⁵ Department of Otolaryngology Head and Neck Surgery, Gongli Hospital, the Second Military Medical University, Shanghai, 200135, China. hsxent@163.com.

Abstract

Background: Lymphangiogenesis has been reported to play crucial roles in the metastasis of thyroid cancer (THCA), but despite the significant research on lymphangiogenesis in THCA, the precise regulatory mechanism remains unclear.

Methods: Public databases including the Cancer Genome Atlas (TCGA), TIMER, and UALCAN were used to analyze and visualize the expression of TET3 and AHR in THCA, and the correlation between these molecules were used by TIMER. Additionally, RT-PCR and Western Blot were performed to determine the mRNA and protein expression of related proteins. Plate colony formation, wound healing, cell cycle, apoptosis, angiogenesis and transwell assay were used to examine the ability of proliferation, movement, lymphangiogenesis, migration and invasion of THCA cells.

Results: Analysis of the TCGA database revealed higher expression levels of TET3 and AHR in tumor tissue compared to normal tissue in THCA. Additionally, a strong correlation was observed between TET3 and AHR. UALCAN database demonstrated that high expression of TET3 and AHR was associated with advanced THCA TNM stages in THCA patients. Furthermore, TET3 activation accelerated THCA cell proliferation by inducing G2/M phase arrest and suppressing apoptosis, while AHR inactivation reduced THCA cell proliferation by decreasing G2/M phase arrest and promoting apoptosis in vitro. Notably, both TET3 and AHR significantly enhanced THCA cell lymphangiogenesis, migration and invasion. Moreover, TET3 activation and AHR inactivation regulated HIF-1α/VEGF signaling pathway, which ultimately, blocked the HIF-1α/VEGF in THCA cells and impaired their movement, migration and invasion abilities.

Conclusions: The combined action of TET3 and AHR to promote lymphangiogenesis in THCA through the HIF-1α/VEGF signaling pathway, and targeting them might provide a potential treatment strategy for THCA.

Keywords: AHR; HIF-1α/VEGF signaling pathway; Lymphangiogenesis; TET3; Thyroid cancer.